Name	Value
Compound	Tofacitinib (CP-690.550)
Investigated event	Influence on Th differentiation
Experiment type	[3H] thymidine incorporation
Concentration	30.00 nM
Cell line	Naïve CD4+ T
Organism	Mus musculus
Animal model	c57BL/6
STAT protein
Other

Low dose CP-690,550 (tofacitinib), a pan-JAK inhibitor, accelerates the onset of experimental autoimmune encephalomyelitis by potentiating Th17 differentiation. Biochemical and biophysical research communications Hideyuki Yoshida, Akihiro Kimura, Tomohiro Fukaya, Takashi Sekiya, Rimpei Morita, Takashi Shichita, Hiromasa Inoue, Akihiko Yoshimura, 418, 2, 2012-02-10, 2012-01-09, 10.1016/j.bbrc.2011.12.156 DOI: 10.1016/j.bbrc.2011.12.156 PUBMED: 22252297 PMCID: 22252297